List of Excipients in Branded Drug ARTICADENT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dentsply Pharmaceutical	ARTICADENT	articaine hydrochloride and epinephrine bitartrate	66312-601	SODIUM CHLORIDE
Dentsply Pharmaceutical	ARTICADENT	articaine hydrochloride and epinephrine bitartrate	66312-601	SODIUM HYDROXIDE
Dentsply Pharmaceutical	ARTICADENT	articaine hydrochloride and epinephrine bitartrate	66312-601	SODIUM METABISULFITE
Dentsply Pharmaceutical	ARTICADENT	articaine hydrochloride and epinephrine bitartrate	66312-601	WATER

Last updated: October 14, 2026

Articadent is a mature articaine hydrochloride and epinephrine dental anesthetic with limited conventional patent protection and low formulation complexity. Its commercial opportunity is driven by supply reliability, cartridge compatibility, preservative and sulfite positioning, lower-waste packaging, and differentiated epinephrine concentrations rather than new chemical-entity exclusivity. The core formulation contains articaine hydrochloride, epinephrine, sodium chloride, sodium metabisulfite, and water for injection. [1]

ARTICADENT Excipient Strategy and Commercial Opportunities

What is Articadent and what formulation does it use?

Articadent is a sterile dental injection containing 4% articaine hydrochloride with epinephrine. It is marketed in two epinephrine strengths:

Product presentation	Articaine hydrochloride	Epinephrine	Primary clinical positioning
Articadent 1:100,000	40 mg/mL	0.01 mg/mL	Greater vasoconstrictor effect and longer hemostasis
Articadent 1:200,000	40 mg/mL	0.005 mg/mL	Lower epinephrine exposure where clinically appropriate

A standard 1.7 mL cartridge contains approximately 68 mg of articaine hydrochloride. The epinephrine content is approximately 0.017 mg in the 1:100,000 presentation and 0.0085 mg in the 1:200,000 presentation. [1]

The labeled inactive ingredients are:

• Sodium chloride
• Sodium metabisulfite
• Water for injection

The formulation is acidic, with a labeled pH range generally reported at approximately 3.6 to 4.4. The acidic pH supports epinephrine stability and helps maintain product quality during shelf life. [1]

What excipients are used in Articadent?

Sodium chloride

Sodium chloride adjusts tonicity and contributes to injection tolerability. A near-isotonic formulation reduces the risk of local irritation compared with a substantially hypotonic or hypertonic solution.

Sodium chloride has limited differentiation value because it is a standard parenteral excipient. Its commercial importance is functional rather than proprietary. Changes to its concentration would require justification through osmolality, local tolerance, and stability data.

Sodium metabisulfite

Sodium metabisulfite is an antioxidant used to protect epinephrine from oxidative degradation. Epinephrine is sensitive to oxygen, light, elevated temperature, and alkaline conditions. The sulfite system is therefore central to maintaining potency and limiting discoloration.

The excipient also creates a labeling and market-positioning issue. Sulfite sensitivity is a known concern for some patients, although dental local anesthetic labeling distinguishes sulfite reactions from allergic reactions to amide anesthetics. [1]

A preservative-free or sulfite-reduced version could have commercial appeal, but removing or materially reducing sodium metabisulfite would require a replacement stabilization strategy. Potential approaches include:

• Improved oxygen control during filling
• Low-oxygen headspace or nitrogen overlay
• Enhanced container closure integrity
• Light-protective primary packaging
• Optimized pH control
• Alternative antioxidant systems, subject to dental and injectable-use acceptability

The central technical constraint is that any alternative antioxidant must protect epinephrine without creating unacceptable toxicity, incompatibility, discoloration, or regulatory burden.

Water for injection

Water for injection is the vehicle. It must meet compendial requirements for sterile injectable products and support the intended pH, osmolality, sterility, and stability profile.

Epinephrine

Epinephrine is an active ingredient rather than an excipient, but it drives the formulation strategy. It provides local vasoconstriction, slows systemic absorption of articaine, prolongs anesthesia, and supports surgical hemostasis.

The 1:100,000 and 1:200,000 strengths allow product segmentation without changing the articaine concentration. This is commercially useful because dentists may select the lower epinephrine strength for patients in whom reduced vasoconstrictor exposure is desirable.

What formulation patents protect Articadent?

Articadent is based on an established local anesthetic formulation rather than a recently introduced molecular platform. The principal commercial and regulatory barriers are therefore product quality, sterile manufacturing, regulatory approval, and cartridge-device compatibility.

Publicly available product information identifies the formulation and labeling requirements but does not establish a current, commercially material patent barrier covering the basic combination of articaine hydrochloride, epinephrine, sodium chloride, sodium metabisulfite, and water for injection. Core composition claims for this type of product are likely to face substantial prior-art pressure because articaine dental injections and epinephrine-containing local anesthetics have long histories of clinical use.

Potentially relevant intellectual-property categories include:

IP category	Potential scope	Commercial significance
Composition claims	Articaine, epinephrine, antioxidant, isotonicity agent, and aqueous vehicle	Likely narrow if directed to conventional concentrations
Stability claims	Sulfite concentration, pH range, oxygen control, or shelf-life performance	Could support differentiated products if narrowly claimed
Cartridge systems	Glass cartridge, stopper, cap, labeling, and compatibility	More relevant to manufacturing and device integration
Manufacturing claims	Filling, oxygen reduction, sterilization, or packaging processes	Can create operational barriers but may be difficult to enforce
Method-of-use claims	Dental anesthesia or procedure-specific use	Limited value where clinical use is established
Packaging claims	Light protection, unit-dose packaging, or tamper evidence	Usually secondary to supply and regulatory execution

No current Orange Book patent or exclusivity conclusion should be inferred solely from the product name. FDA Orange Book status must be checked against the relevant approved application and current listing data. [2]

When does Articadent lose exclusivity?

Articadent is a mature product, and any original new-drug exclusivity or early composition patent protection would not ordinarily remain the principal barrier to competition. The commercial exclusivity period is likely exhausted, subject to the exact approved application, patent records, and any later product-specific rights.

The relevant competitive framework is therefore different from that for a recently approved small molecule:

Exclusivity category	Likely status for a mature articaine dental injection
New chemical entity exclusivity	Expired or not applicable to current competition
Five-year Hatch-Waxman exclusivity	Not a current barrier
Three-year clinical-investigation exclusivity	Not expected to govern the established product
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not expected to be commercially material
Active formulation patents	Must be verified at the application and patent level
Trade-secret protection	Potentially relevant to manufacturing, but not a market exclusivity right

Generic or follow-on competitors can enter through an abbreviated or other applicable FDA pathway if they meet requirements for sameness, bioequivalence where applicable, sterility, labeling, container closure, and manufacturing quality.

What FDA regulatory requirements apply to Articadent excipients?

Articadent is a sterile injectable dental product. The formulation must comply with FDA requirements for drug quality, sterile manufacturing, container closure, labeling, stability, and adverse-event monitoring. [3]

Key regulatory controls include:

1. Identity and assay of articaine hydrochloride.
2. Identity and potency of epinephrine.
3. Control of degradation products.
4. pH and osmolality.
5. Sterility and bacterial endotoxins.
6. Particulate matter.
7. Extractables and leachables from the cartridge and closure.
8. Antioxidant content and sulfite-related labeling.
9. Container closure integrity.
10. Stability under long-term, accelerated, and in-use conditions.

The excipient strategy cannot be evaluated separately from the primary container. Glass cartridge chemistry, elastomer stopper composition, aluminum seal, and oxygen ingress can materially affect epinephrine stability.

A formulation change involving sodium metabisulfite concentration, pH, cartridge material, stopper composition, or fill volume could require a post-approval change, supplemental filing, or new application strategy depending on the scope of the change and the applicable FDA pathway.

Which excipient strategies create commercial opportunities?

1. Sulfite-reduced or sulfite-free product

A sulfite-reduced product could target dentists and patients concerned about sulfite exposure. The opportunity is clinically and commercially credible only if epinephrine stability is maintained across the labeled shelf life.

The main development risk is that epinephrine oxidation can produce potency loss and visible discoloration. A successful product would need a complete stability package, including oxygen exposure studies, photostability, temperature cycling, and container-closure testing.

2. Lower-epinephrine positioning

The existing 1:200,000 product already supports lower epinephrine exposure. A commercial program could refine this segment through clearer procedure-based positioning, packaging differentiation, and inventory management.

The product would not necessarily need a new excipient system. Commercial value could come from:

• Reduced epinephrine exposure messaging
• Use in shorter or less invasive dental procedures
• Lower total vasoconstrictor exposure per appointment
• Distinctive cartridge labeling
• Better differentiation from 1:100,000 products

3. Preservative-free or simplified formulation

Dental cartridges are generally unit-dose products, reducing the need for antimicrobial preservatives. A simplified formulation that minimizes nonessential excipients could appeal to dental groups seeking cleaner labeling and fewer sensitization concerns.

The key question is whether sodium metabisulfite is treated as an essential antioxidant for the selected epinephrine strength. A product that removes sulfite must demonstrate an alternative control strategy rather than merely eliminate the excipient.

4. Improved oxygen and light protection

Packaging innovation may provide a more practical opportunity than new excipient chemistry. Potential approaches include:

• Lower-oxygen filling
• Nitrogen processing
• Enhanced light-protective secondary packaging
• High-barrier cartridge components
• Improved closure systems
• Unit-of-use packaging with controlled storage instructions

These changes can extend shelf life, reduce waste, and improve supply-chain resilience. They may also create manufacturing know-how that is difficult for competitors to reproduce quickly, even if patent protection is narrow.

5. Reduced-waste cartridge systems

Dental practices often manage partial boxes, damaged cartridges, expired inventory, and different epinephrine strengths. Commercial opportunities include packaging that improves:

• Cartridge protection during transport
• Inventory rotation
• Unit-dose traceability
• Bar-code scanning
• Recall management
• Waste reduction

The value proposition is strongest for dental-service organizations and high-volume practices, where procurement and inventory costs are material.

How does Articadent compare with competing dental anesthetics?

Articadent competes primarily with lidocaine, mepivacaine, prilocaine, and other articaine products.

Product class	Main active ingredient	Epinephrine dependence	Excipient opportunity
Articaine with epinephrine	Articaine hydrochloride	Commonly included	Sulfite control, oxygen management, cartridge stability
Lidocaine with epinephrine	Lidocaine hydrochloride	Commonly included	Similar antioxidant and packaging issues
Mepivacaine plain	Mepivacaine hydrochloride	None	Simplified preservative and antioxidant strategy
Prilocaine with epinephrine	Prilocaine hydrochloride	Often included	Antioxidant and vasoconstrictor differentiation
Plain articaine, where approved	Articaine hydrochloride	None	Stability and preservative-free positioning

Articaine’s commercial differentiation comes from its dental use profile and diffusion characteristics, not from a unique excipient system. A new entrant would need to compete on clinical preference, product availability, price, packaging, or procurement terms.

Which companies are challenging or competing with Articadent?

Competition in dental local anesthetics is fragmented. Relevant participants can include:

• Dentsply Sirona and affiliated dental pharmaceutical businesses
• Septodont
• Hikma Pharmaceuticals
• Fresenius Kabi or regional injectable-drug suppliers
• Generic manufacturers and contract manufacturers
• Regional dental anesthesia distributors

The relevant competitive set depends on country, approved concentration, cartridge presentation, and whether the product is supplied directly to dental practices or through distributors.

Paragraph IV risk is likely to be limited for a mature product unless a competitor challenges a still-listed patent covering a specific formulation, cartridge, or use. More important risks are ordinary generic substitution, manufacturing approvals, supply interruptions, and price competition.

What patent litigation or settlement agreements affect Articadent?

No specific current patent litigation or settlement agreement should be attributed to Articadent without a verified case docket, FDA listing, or company disclosure. For a mature dental anesthetic, the most likely disputes would concern:

• ANDA patent certifications
• Cartridge or closure patents
• Formulation-stability claims
• Trade dress and labeling
• Manufacturing process rights
• Distribution or licensing contracts

A settlement could delay entry, but any such conclusion requires a documented agreement and corresponding regulatory or court record. The core articaine-epinephrine formulation is unlikely to support a durable litigation-based moat by itself.

What geographic opportunities exist for Articadent excipients?

The commercial opportunity varies by regulatory market.

United States

The FDA market emphasizes sterile manufacturing, container closure, sulfite labeling, and approved-product comparability. A follow-on product may compete through an approved abbreviated or full application pathway depending on regulatory classification.

European Union

The European market is fragmented by national reimbursement, procurement, and dental practice preferences. Variations in cartridge size, epinephrine strength, and labeling can require country-specific commercialization work.

Emerging markets

Growth opportunities are more likely to come from reliable supply, affordable unit-dose packaging, and local manufacturing or fill-finish partnerships. Excipient sourcing must meet pharmacopoeial requirements and maintain consistent epinephrine stability under difficult distribution conditions.

Heat and oxygen exposure are particularly important in markets with less controlled logistics. A formulation and packaging system that tolerates distribution variability could command value even without strong patent protection.

How strong is the Articadent patent estate?

The patent estate appears strategically weak as a standalone barrier if assessed only on the conventional drug composition. The stronger defensibility areas are likely to be:

1. Manufacturing consistency for sterile cartridges.
2. Epinephrine stability over the full shelf life.
3. Container closure and oxygen control.
4. Reliable supply of dental cartridges.
5. Regulatory history and approved labeling.
6. Customer relationships with dental distributors and group practices.

A new entrant could therefore achieve a defensible position through a combined formulation, packaging, manufacturing, and distribution strategy. A patent-only approach would likely have limited value unless it covers a genuinely differentiated low-sulfite system, container, or stability result.

What generic launch scenarios exist for Articadent?

Price-led generic entry

A manufacturer could use the conventional formulation and compete on acquisition cost. This is the most direct threat to an established branded product.

Supply-led entry

A competitor could win share by maintaining reliable availability during shortages or manufacturing disruptions. Dental practices may switch products quickly when local anesthetic supply is constrained.

Formulation-differentiated entry

A lower-sulfite, improved-stability, or distinct epinephrine-strength product could command a premium if supported by clinical and regulatory evidence.

Packaging-led entry

A supplier could differentiate with better cartridge protection, traceability, lower breakage, or more efficient case configurations.

Contract-manufacturing entry

A dental company without its own sterile facility could license or outsource production. This can accelerate market entry but increases dependence on the contract manufacturer’s capacity, quality systems, and regulatory compliance.

Key Takeaways

• Articadent is a mature 4% articaine hydrochloride dental injection with 1:100,000 and 1:200,000 epinephrine presentations.
• The principal excipients are sodium chloride, sodium metabisulfite, and water for injection.
• Sodium metabisulfite is the most commercially consequential excipient because it stabilizes epinephrine but creates sulfite-related labeling and positioning considerations.
• The strongest development opportunities are sulfite reduction, oxygen-control packaging, improved cartridge systems, and lower-waste distribution.
• Conventional composition patents are unlikely to provide a strong current market barrier without a narrowly differentiated stability or packaging invention.
• Generic entry risk is driven more by FDA approval, sterile manufacturing, supply reliability, and price than by active primary patents.
• The 1:200,000 epinephrine strength provides an existing platform for lower-epinephrine commercial segmentation.
• Geographic opportunities depend on cartridge supply, regulatory approval, climate-controlled logistics, and dental procurement structures.

FAQs

Is sodium metabisulfite necessary in Articadent?

It is used to protect epinephrine from oxidation. Removing or reducing it would require an alternative stability strategy and supporting regulatory data.

Can Articadent be reformulated without epinephrine?

A plain articaine product may be technically possible where approved, but removing epinephrine changes vasoconstriction, duration, systemic absorption, clinical positioning, and stability requirements.

What is the most attractive excipient innovation for Articadent?

A validated low-sulfite or sulfite-free system with strong epinephrine stability would have the clearest formulation differentiation. Improved oxygen-control packaging is a potentially lower-risk alternative.

Does Articadent have biologic or biosimilar risk?

No. Articadent is a small-molecule sterile injectable. Biosimilar pathways do not apply. Competition would arise from generic or follow-on drug products.

What is the main commercial risk for an Articadent competitor?

The main risks are sterile manufacturing failure, epinephrine degradation, cartridge incompatibility, product shortages, and difficulty securing dental-distributor access.

References

1. U.S. Food and Drug Administration. (n.d.). Articadent: Articaine hydrochloride and epinephrine injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21: Current good manufacturing practice for finished pharmaceuticals.